Format

Send to

Choose Destination
Psychopharmacology (Berl). 2016 Oct;233(19-20):3603-13. doi: 10.1007/s00213-016-4397-4. Epub 2016 Aug 9.

Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.

Author information

1
School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK.
2
School of Chemistry, Food and Pharmacy, University of Reading, Reading, UK.
3
GW Research Ltd, Cambridge, UK.
4
School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK. claire.williams@reading.ac.uk.

Abstract

RATIONALE:

The appetite-stimulating properties of cannabis are well documented and have been predominantly attributed to the hyperphagic activity of the psychoactive phytocannabinoid, ∆(9)-tetrahydrocannabinol (∆(9)-THC). However, we have previously shown that a cannabis extract devoid of ∆(9)-THC still stimulates appetite, indicating that other phytocannabinoids also elicit hyperphagia. One possible candidate is the non-psychoactive phytocannabinoid cannabigerol (CBG), which has affinity for several molecular targets with known involvement in the regulation of feeding behaviour.

OBJECTIVES:

The objective of the study was to assess the effects of CBG on food intake and feeding pattern microstructure.

METHODS:

Male Lister hooded rats were administered CBG (30-120 mg/kg, per ora (p.o.)) or placebo and assessed in open field, static beam and grip strength tests to determine a neuromotor tolerability profile for this cannabinoid. Subsequently, CBG (at 30-240 mg/kg, p.o.) or placebo was administered to a further group of pre-satiated rats, and hourly intake and meal pattern data were recorded over 2 h.

RESULTS:

CBG produced no adverse effects on any parameter in the neuromotor tolerability test battery. In the feeding assay, 120-240 mg/kg CBG more than doubled total food intake and increased the number of meals consumed, and at 240 mg/kg reduced latency to feed. However, the sizes or durations of individual meals were not significantly increased.

CONCLUSIONS:

Here, we demonstrate for the first time that CBG elicits hyperphagia, by reducing latency to feed and increasing meal frequency, without producing negative neuromotor side effects. Investigation of the therapeutic potential of CBG for conditions such as cachexia and other disorders of eating and body weight regulation is thus warranted.

KEYWORDS:

Appetite; Appetitive; Cachexia; Cannabigerol; Cannabis; Consummatory; Feeding; Hyperphagia; Phytocannabinoid; Tolerability

PMID:
27503475
PMCID:
PMC5021742
DOI:
10.1007/s00213-016-4397-4
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

The work reported was funded in part by grants to BJW and CMW from GW Research and Otsuka Pharmaceuticals. The original study concept was discussed with the sponsor (GW Research), although all subsequent study design, data collection, analysis and interpretation were conducted independently by the authors. The report was approved by the sponsor company prior to submission, and the authors retain full control of all primary data.

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center